Supplier of speciality ingredients Croda is celebrating two achievements in relation to EXCiPACT, the voluntary scheme that reduces the audit burden in the pharmaceutical industry by providing independent third party certification of manufacturers, suppliers and distributors of excipients.
In the same month in which Croda joined the first few companies to be awarded the prestigious EXCiPACT Certificate, Croda’s Head of Global Quality Assurance Iain Moore was singled out as a “leading light” in driving EXCiPACT forward in a speech by Frank Milek, Chair of The International Pharmaceutical Excipients Council Europe at their annual seminar in Cannes. “Iain has been involved right from the beginning,” said Milek. “The time and the empathy Iain invested into this project was a major contribution to make it work. I do not think to exaggerate Iain's merits when I say that EXCiPACT would not have happened or would have established much, much later without his engagement into this project.”
Croda’s first EXCiPACT certification covers ingredients manufactured at Rawcliffe Bridge in the UK. This achievement is part of a global programme to gain accreditation at the six Croda sites that supply pharmaceutical excipients. “This achievement is a real win-win for Croda and our customers,” commented Sandra Breene, President of Croda’s Consumer Care business in Europe. “It reduces the audit burden on both sides whilst maintaining confidence in Croda’s compliance to the demanding standards of the Pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT GMP standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards.”
Croda’s proactive commitment to EXCiPACT provides a reinforcement of the company’s dedication to quality and customer support.
Croda, +44 1405 860551, nicola.daniels@croda.com, www.croda.com/healthcare.